menu
    • menu
    [{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MSIDS Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-absorbable Film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Vizient"},{"orgOrder":0,"company":"Elutia","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Financing","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Elutia","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Elutia \/ Lake Street Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Rifampicin

    Menu

    Rifampicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand

                            Details : EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Vizient

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

                            Details : The agreement aims to provide access to Elutia’s innovative EluPro Antibiotic Eluting BioEnvelope, embedded with rifampin and minocycline, to S3P’s extensive network of 993 acute care facilities.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Vizient

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elutia Implants First EluPro™, a Drug-Eluting BioEnvelope for Cardiac Use

                            Details : EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 05, 2024

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lake Street Capital Markets

                            Deal Size : $15.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

                            Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix product EluPro (rifampin), the world’s first antibiotic-eluting BioEnvelope for Post-surgical Infections.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lake Street Capital Markets

                            Deal Size : $15.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elutia Wins FDA Clearance for EluPro™, an Antibiotic-Eluting BioEnvelope

                            Details : EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 17, 2024

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

                            Details : CanGaroo RM featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection is under evaluation for post-surgical infections.

                            Product Name : CanGaroo RM

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 18, 2023

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Berkeley Biologics

                            Deal Size : $35.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million

                            Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

                            Product Name : CanGaroo RM

                            Product Type : Small molecule

                            Upfront Cash : $35.0 million

                            November 09, 2023

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Berkeley Biologics

                            Deal Size : $35.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : HighCape Capital

                            Deal Size : $26.2 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Elutia Announces Private Placement for Proceeds up to $26 Million

                            Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

                            Product Name : CanGaroo

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 19, 2023

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : HighCape Capital

                            Deal Size : $26.2 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Elutia

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Berkeley Biologics

                            Deal Size : $35.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million

                            Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

                            Product Name : CanGaroo

                            Product Type : Small molecule

                            Upfront Cash : $35.0 million

                            September 18, 2023

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Berkeley Biologics

                            Deal Size : $35.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Citius Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Citius Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

                            Details : Citius intends to use the net proceeds for pre-clinical and clinical development of its product candidates, including Mino-Wrap, a malleable, bio-absorbable film impregnated with minocycline and rifampin used in patients that elect to undergo reconstruct...

                            Product Name : Mino-Wrap

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Minocycline Hydrochloride,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth